AMGN Stock - Amgen Inc.
Unlock GoAI Insights for AMGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $33.42B | $28.19B | $26.32B | $25.98B | $25.42B |
| Gross Profit | $20.57B | $19.77B | $19.92B | $19.52B | $19.27B |
| Gross Margin | 61.5% | 70.1% | 75.7% | 75.2% | 75.8% |
| Operating Income | $7.26B | $7.90B | $9.57B | $7.64B | $9.14B |
| Net Income | $4.09B | $6.72B | $6.55B | $5.89B | $7.26B |
| Net Margin | 12.2% | 23.8% | 24.9% | 22.7% | 28.6% |
| EPS | $7.62 | $12.56 | $12.18 | $10.34 | $12.40 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 5th 2025 | Erste Group | Upgrade | Buy | - |
| November 24th 2025 | Truist | Resumed | Hold | $318 |
| November 13th 2025 | Scotiabank | Initiation | Sector Outperform | $385 |
| September 3rd 2025 | Raymond James | Resumed | Market Perform | - |
| May 20th 2025 | Guggenheim | Resumed | Neutral | $288 |
| April 22nd 2025 | Cantor Fitzgerald | Resumed | Neutral | $305 |
| December 10th 2024 | BofA Securities | Resumed | Underperform | $256 |
| November 15th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| November 14th 2024 | Citigroup | Initiation | Neutral | $335 |
| October 17th 2024 | Bernstein | Initiation | Outperform | $380 |
| October 14th 2024 | Truist | Downgrade | Hold | $333← $320 |
| September 27th 2024 | Cantor Fitzgerald | Initiation | Overweight | $405 |
| August 7th 2024 | Wells Fargo | Downgrade | Equal Weight | $335← $320 |
| May 3rd 2024 | Barclays | Upgrade | Equal Weight | $300← $230 |
| May 3rd 2024 | William Blair | Upgrade | Outperform | - |
Earnings History & Surprises
AMGNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $4.73 | — | — | — |
Q4 2025 | Nov 4, 2025 | $5.02 | $5.64 | +12.4% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $5.28 | $6.02 | +14.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $4.27 | $4.90 | +14.8% | ✓ BEAT |
Q1 2025 | Feb 4, 2025 | $5.04 | $5.31 | +5.4% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $5.11 | $5.58 | +9.2% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $4.98 | $4.97 | -0.2% | ✗ MISS |
Q2 2024 | May 2, 2024 | $3.88 | $3.96 | +2.1% | ✓ BEAT |
Q1 2024 | Feb 6, 2024 | $4.59 | $4.71 | +2.6% | ✓ BEAT |
Q4 2023 | Oct 31, 2023 | $4.65 | $4.96 | +6.7% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $4.44 | $5.00 | +12.6% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $3.85 | $3.98 | +3.4% | ✓ BEAT |
Q1 2023 | Jan 31, 2023 | $4.04 | $4.09 | +1.2% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $4.44 | $4.70 | +5.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $4.40 | $4.65 | +5.7% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $4.22 | $4.25 | +0.7% | ✓ BEAT |
Q1 2022 | Feb 7, 2022 | $4.08 | $4.36 | +6.9% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $4.22 | $4.67 | +10.7% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $4.13 | $4.38 | +6.1% | ✓ BEAT |
Latest News
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralAmgen Reaches U.S. Government Agreement To Lower Drug Prices, Expand Direct-To-Patient Access And Reinforce U.S. Manufacturing Investment
📈 PositiveSenior Administration Official Says President Trump To Announce Deals With Nine Pharmaceutical Companies To Reduce Drug Prices; Deals Are With Amgen, Bristol Myers Squibb, Roche's GenenTech, Gilead, GSK, Merck, Novartis, Sanofi And Boehringer Ingelheim; Each Manufacturer Agrees To Reduce Prices On Majority Of Medications Sold Through Medicaid; Companies Commit To $150B In New Investment In Manufacturing And R&D In U.S.
📈 PositiveMorgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $304
➖ NeutralReported Earlier, Amgen Announces FDA Approval Of UPLIZNA For Anti-AChR And Anti-MuSK Ab+ Generalized Myasthenia Gravis With Twice-Yearly Dosing After Loading Doses
📈 PositiveWells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $325
➖ NeutralBMO Capital Maintains Outperform on Amgen, Raises Price Target to $372
📈 PositiveTruist Securities Assumes Amgen at Hold, Raises Price Target to $318
➖ NeutralReported November 19, 2025: Amgen's IMDELLTRA Receives FDA Approval For Extensive Stage Small Cell Lung Cancer After Phase 3 Trial Shows 40% Reduction In Death Risk Compared To Chemotherapy
📈 PositiveFDA Grants Accelerated Approval To Sevabertinib For Non-Squamous Non-Small Cell Lung Cancer
📈 PositiveLive On CNBC, Josh Brown Hosts Segment Titled "Best Stocks In The Market: AbbVie; Amgen; Eli Lilly "
📈 PositivePiper Sandler Maintains Overweight on Amgen, Raises Price Target to $381
📈 PositiveAmgen's Repatha Cuts Risk Of First Major Adverse Cardiovascular Events By 25%, Heart Attack Risk By 36% In Phase 3 Vesalius-CV Trial
📈 PositiveWatching Amgen; Hearing Investor Business Daily SwingTrader Buys Stock
📈 PositiveCantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $315
➖ NeutralMorgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $329
📉 NegativeAmgen shares are trading higher following strong Q3 earnings and raised FY25 guidance.
📈 PositiveWells Fargo Maintains Overweight on Amgen, Raises Price Target to $300
📈 PositiveAmgen Raises FY2025 Sales Guidance from $35.000B-$36.000B to $35.800B-$36.600B vs $35.659B Est
📈 PositiveAmgen Raises FY2025 GAAP EPS Guidance from $10.97-$12.11 to $13.76-$14.60 vs $11.36 Est
📈 PositiveFrequently Asked Questions about AMGN
What is AMGN's current stock price?
What is the analyst price target for AMGN?
What sector is Amgen Inc. in?
What is AMGN's market cap?
Does AMGN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AMGN for comparison